Please visit answersincme.com/BJV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancers discusses CD19-directed CAR T-cell therapies in patients with relapsed/refractory large B-cell lymphoma. Upon completion of this activity, participants should be better able to: Review the rationale for CD19-directed CAR T-cell therapies in patients with R/R LBCL who have early relapse after frontline chemoimmunotherapy; Discuss the clinical profiles of available CD19-directed CAR T-cell therapies for patients with R/R LBCL who have early relapse after frontline chemoimmunotherapy; and Outline patient-centered strategies for optimizing treatment with CD19-directed CAR T-cell therapies in patients with R/R LBCL who have early relapse after frontline chemoimmunotherapy.